 Passage Bio NASDAQ:IMRA was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Saturday, Zacks.com reports. According to Zacks, Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin. The companys ... 